Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 9 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $14.9M in total
- 9
- 13F holdersQ2 2026, +3 vs. previous quarter
- 202
- 13F valueReported value at the end of Q2 2026
- $2.50B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IMNM, Q2 2026
No superinvestor reported holding IMNM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immunome Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 11 | 4 days | Higgins JackChief Scientific Officer | SSale | −13.2K | $25.32 | −$334.2K | −16.9%65.0K after | 10b5-1 |
| Aug 12, 2026 (view filing)5:47 PM ET | Aug 10-11 | 2 days | Barchas IsaacDirector | SSale | −72.4K | $26.21 | −$1.90M | −100.0%0 after | 2 lots10b5-1 |
| Aug 12, 2026 (view filing)5:47 PM ET | Aug 12 | Same day | Barchas IsaacDirector | SSale | −11.0K | $27.25 | −$301.1K | −10.7%92.2K after | 10b5-1 |
| Aug 10, 2026 (view filing)4:10 PM ET | Aug 6-7 | 4 days | Barchas IsaacDirector | SSale | −36.1K | $26.06 | −$940.5K | −33.3%72.4K after | 2 lots10b5-1 |
| Aug 6, 2026 (view filing)6:30 PM ET | Aug 4 | 2 days | Horn KinneyCHIEF BUSINESS OFFICER | SSale | −90.6K | $25.09 | −$2.27M | −100.0%0 after | 10b5-1 |
| Jul 9, 2026 (view filing)5:38 PM ET | Jul 7 | 2 days | Horn KinneyCHIEF BUSINESS OFFICER | SSale | −1.09K | $25.00 | −$27.3K | −100.0%0 after | 10b5-1 |
| Jul 7, 2026 (view filing)7:02 PM ET | Jul 6-7 | 1 day | Barchas IsaacDirector | SSale | −100.0K | $24.13 | −$2.41M | −48.0%108.5K after | 2 lots10b5-1 |
| Jul 7, 2026 (view filing)5:42 PM ET | Jul 2 | 5 days | Lechleider RobertChief Medical Officer | SSale | −55.0K | $22.62 | −$1.24M | −77.7%15.8K after | 3 lots10b5-1 |
| Jul 2, 2026 (view filing)8:31 PM ET | Jun 30-Jul 2 | 2 days | Barchas IsaacDirector | SSale | −201.1K | $21.85 | −$4.39M | −49.1%208.5K after | 3 lots10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25 | 4 days | Lechleider RobertChief Medical Officer | SSale | −55.0K | $19.85 | −$1.09M | −77.7%15.8K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Immunome Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19,676,883 | $417.0M | 0.27% | +3,312,872+20.2% | Added |
| FMR LLC | 16,987,553 | $360.0M | 0.02% | +17,599+0.1% | Added |
| BlackRock, Inc. | 8,805,492 | $186.6M | 0.00% | +636,818+7.8% | Added |
| State Street Corp | 5,494,625 | $116.4M | 0.00% | +94,724+1.8% | Added |
| Wellington Management Group LLP | 5,210,216 | $110.4M | 0.02% | +478,239+10.1% | Added |
| Redmile Group, LLC | 4,911,590 | $104.1M | 6.99% | −647,295−11.6% | Reduced |
| Primecap Management Co | 4,581,431 | $97.1M | 0.06% | −206,800−4.3% | Reduced |
| Vanguard Capital Management LLC | 4,551,289 | $96.4M | 0.00% | +121,592+2.7% | Added |
| Driehaus Capital Management LLC | 4,346,139 | $92.1M | 0.53% | +246,238+6.0% | Added |
| Enavate Sciences GP, LLC | 3,613,799 | $76.6M | 22.17% | 00.0% | Unchanged |